DISCOVER THE DUPIXENT DIFFERENCE
Only DUPIXENT directly inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation.1,*
*The mechanism of dupilumab action has not been definitively established.
Make DUPIXENT Your
First-Choice
Biologic
#1 PRESCRIBED BIOLOGIC BY ALLERGISTS AND PULMONOLOGISTS2,3,a,b
Prescribed to >208,000 asthma patients by >31,600 healthcare providers in the United States4,c,d
a#1 prescribed biologic by allergists includes the aggregate number of new to brand across indications. Source: Data on file, Sanofi US. New to Brand Weekly Audit;
data through December 2025.
b#1 prescribed biologic by pulmonologists includes the aggregate number of new to brand across indications. Source: Data on file, Sanofi US. New to Brand Weekly Audit;
data through February 2026.
cDU Patient View; data through January 2, 2026.
dNew adult and pediatric patients aged 6 years and older with moderate-to-severe eosinophilic or OCS‑dependent asthma.
Explore Multiple Dosage and Administration Options
Offer your patients 6 years and older flexible administration: at home or in office1
DUPIXENT is the Only Biologic that Combines the Ability to:
Target
More Than One
Source of
Type 2 Inflammation by
Specifically Inhibiting
- IL-4 and IL-13 are two of the key drivers of local and systemic type 2 inflammation1,5,*
*The mechanism of dupilumab action has not been definitively established.1
Explorethe MoA
Treat
More Than One
Asthma
Patient Type
- Specifically indicated for OCS-dependent asthma patients and for moderate-to-severe asthma patients with eosinophilic phenotype1
-
Markers of type 2 inflammation: Proven data in indicated patients with ≥1 of the
following6,7:
- EOS ≥150 cells/µL
- IgE ≥30 IU/mLe
- FeNO ≥20 ppb
PATIENT TYPES
Control
More Than One
Measure of
Uncontrolled Asthma
- Exacerbation reduction: Up to 81% significant reduction in annualized rate of severe exacerbations through Week 241,f
- Lung function improvement: Rapid FEV1 improvement at Week 2g and sustained through Week 521,8,h
- OCS reduction/elimination: 86% of patients reduced or eliminated their OCS dose at Week 249,i
and Safety Data
ePlus ≥1 positive perennial-aeroallergen–specific IgE ≥0.35 kU/L at baseline.7
fWith DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (DRI12544, EOS ≥300 cells/µL, secondary endpoint).1
g~72% of the total FEV1 improvement was seen at Week 2 with DUPIXENT 200 mg Q2W + SOC (n=264) (QUEST, EOS ≥300 cells/µL, secondary endpoint).1,8
h470 mL sustained breathing relief was seen at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint).1
iWith DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (VENTURE, ITT population).9
EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ITT, intention-to-treat; OCS, oral corticosteroid; Q2W, once every 2 weeks, SOC, standard of care.
Not an actual DUPIXENT patient.
Help eligible patients start and stay on track with DUPIXENT
DUPIXENT MyWay is a patient support program that offers insurance coverage support, financial assistance, and resources to help eligible patients who are prescribed DUPIXENT.
99%
of OCS-dependent asthma patients who are commercially insured required no biomarker testing10
~99%
of commercially insured patients nationally are covered for DUPIXENT10,j,k
jThe Dedham Group Quality of Access
Tracking Report. March 2024.
kCoverage varies by type and plan.
Check formulary status in your area
See insurance coverage status, prior authorization, and step edit information for DUPIXENT.
Look up coverage